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Abstract
The incidence of osteoporosis and cardiovascular disease increases with age, and there are potentially shared mechanis-
tic associations between the two conditions. It is therefore highly relevant to understand the cardiovascular implications 
of osteoporosis medications. These are presented in this narrative review. Calcium supplementation could theoretically 
cause atheroma formation via calcium deposition, and in one study was found to be associated with myocardial infarction, 
but this has not been replicated. Vitamin D supplementation has been extensively investigated for cardiac benefit, but no 
consistent effect has been found. Despite findings in the early 21st century that menopausal hormone therapy was associ-
ated with coronary artery disease and venous thromboembolism (VTE), this therapy is now thought to be potentially safe 
(from a cardiac perspective) if started within the first 10 years of the menopause. Selective estrogen receptor modulators 
(SERMs) are associated with increased risk of VTE and may be related to fatal strokes (a subset of total strokes). Bisphos-
phonates could theoretically provide protection against atheroma. However, data from randomised trials and observational 
studies have neither robustly supported this nor consistently demonstrated the potential association with atrial fibrillation. 
Denosumab does not appear to be associated with cardiovascular disease and, although parathyroid hormone analogues are 
associated with palpitations and dizziness, no association with a defined cardiovascular pathology has been demonstrated. 
Finally, romosozumab has been shown to have a possible cardiovascular signal, and therefore post-market surveillance of 
this therapy will be vital.
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 cc@mrc.soton.ac.uk
Extended author information available on the last page of the article
Key Points 
Osteoporosis and cardiovascular disease are the potential 
consequences of shared mechanisms.
Anti-osteoporosis medications are associated with poten-
tial increases in cardiac risk (romosozumab, calcium 
supplementation, menopausal hormonal therapy), no 
effect on cardiac risk (vitamin D) or reduced cardiac risk 
(bisphosphonates).
Selective estrogen receptor modulators, such as ralox-
ifene, and menopausal hormonal therapy are associated 
with increased risk of venous thromboembolic disease.
Romosozumab therapy is contra-indicated in those with 
a history of myocardial infarction or ischaemic stroke.
1 Introduction
Osteoporosis is characterised by a reduction in bone min-
eral density and an increased risk of fractures. As with 
cardiovascular disease, the prevalence increases in older 
age so that osteoporosis and cardiovascular disease (and 
cardiovascular risk factors) often coexist in the same 
patient. Given the age group of patients with osteoporosis 
[1], the occurrence of cardiovascular morbidity is a sig-
nificant consideration. Any interventions associated with 
an increased cardiovascular risk should be identified and 
clear guidance provided on their prescription to maximise 
the benefit–risk of any potential therapy. We are therefore 
left with a central question, namely, “To what extent are 
the available drug therapies for osteoporosis associated 
with cardiovascular adverse events?” In order to answer 
this question, an expert working group was convened by 
the European Society for Clinical and Economic Aspects 
of Osteoporosis, Osteoarthritis and Musculoskeletal Dis-
orders (ESCEO) and by the International Osteoporosis 
Foundation (IOF). The available evidence was reviewed 
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on calcium supplements, vitamin D replacement, meno-
pausal hormone therapy (MHT), selective estrogen recep-
tor modulators (SERMs), bisphosphonates, denosumab, 
parathyroid hormone (PTH) analogues and romosozumab.
2  Calcium Supplementation
Inadequate calcium consumption is associated with an 
increased risk of fragility fracture and deterioration in 
bone mineral density [2]. Therefore calcium supplements 
can be beneficial for bone health. However, high con-
sumption of calcium could theoretically lead to arterial 
and soft tissue calcification, the development of athero-
sclerotic plaques and cardiovascular morbidity. Although 
considerable current research has suggested a relation-
ship between pharmacological calcium supplementation 
and the risk of heart disease, critical evaluation of this 
literature suggests that the observed associations may not 
be of clinical relevance.
Safety events can be mislabelled. This was the case in 
a 2006 randomised, placebo-controlled trial of calcium 
supplementation in osteoporosis, in which the incidence of 
ischaemic heart disease (IHD) in the calcium supplemen-
tation group was not significantly different to that in the 
placebo group (7.7% vs 7.0%, hazard ratio [HR] 1.12, 95% 
confidence interval [CI] 0.77–1.64). This was despite the 
fact that gastrointestinal adverse events were misclassified 
as IHD, which would potentially lead to exaggeration of 
the effect of calcium supplementation on cardiovascular 
health [3]. However, randomised placebo-controlled trials 
have often been powered to address the primary outcome 
(change in bone density or fracture), rather than cardio-
vascular safety. This focus serves to limit the assessment 
of safety-associated endpoints.
In order to address this issue, Bolland et al. performed 
the Auckland Calcium Trial, which compared calcium (1 g 
of elemental calcium as citrate salt daily) versus placebo in 
730 women over 60 months and focused on cardiovascular 
health as the primary outcome [4]. The results showed that 
there was an increased risk of myocardial infarction (MI) in 
the calcium group (risk ratio [RR] 2.24, 95% CI 1.20–4.17).
This was very much the ‘index finding’ in the investiga-
tion of calcium supplementation and cardiac risk, but there 
are several important issues to note. Firstly, the baseline 
cardiovascular status of the calcium and placebo groups 
was different, with the calcium group having a greater bur-
den of cardiovascular disease than the placebo group. Sec-
ondly, there was a trend towards a reduced risk of angina 
in the calcium group (RR 0.71, 95% CI 0.50–1.01), which 
is puzzling, considering that both MI and angina can (in 
the case of unstable angina) sit under the bracket of ‘acute 
coronary syndromes’. Thirdly, in this study, cardiovascular 
events were self-reported and then adjudicated via health 
records, which could introduce reporting bias. The adjudica-
tion reduced the effect size of the risk of MI, with the lower 
band of the 95% CI dropping to 1.01, bordering significance. 
These issues, together with the evidence from the Women’s 
Health Initiative (WHI) trial of calcium and vitamin D, 
which found no adverse effect signal (MI/coronary death HR 
1.04, 95% CI 0.92–1.18; stroke HR 0.95, 95% CI 0.82–1.10) 
[5], made it difficult to interpret the cardiovascular effect of 
calcium supplementation, and warranted further examina-
tion through data assimilation.
Fifteen calcium trials were meta-analysed, and a signifi-
cantly increased risk of MI was observed (HR 1.27, 95% 
CI 1.01–1.59), although there was no excess risk of stroke, 
death or the composite endpoint in the trial-level data [6]. 
However, in individual patient-level analyses, there was an 
interaction between treatment and dietary calcium intake 
when the outcome of interest was MI. This interaction was 
observed in the patients with a spontaneous calcium intake 
above, but not below, the median. Thus, clarity was sought 
through further interrogation of the WHI calcium trial 
dataset in a meta-analysis together with seven other stud-
ies [7] to distil out the effect of personal supplementation 
alongside calcium supplementation. In those patients who 
were not taking over-the-counter calcium or vitamin D sup-
plements, there was a 13% increase in the risk of cardio-
vascular events in those in the calcium arm (HRs from 1.13 
to 1.22, p values ranging from 0.04 to 0.05) [7]. However, 
those who were taking over-the-counter supplements at the 
time of the study were at no increased risk of cardiovas-
cular events. Calcium or calcium and vitamin D increased 
the risk of MI (HR 1.24, 95% CI 1.07–1.45) and the com-
posite of MI or stroke (HR 1.15, 95% CI 1.03–1.27). The 
authors concluded that there was an increased risk of MI 
and stroke due to calcium supplementation and that this 
had been “obscured” in the previous WHI study by the 
use of personal calcium and vitamin D supplements. There 
are a few caveats to this assertion [8]. Firstly, if Bonfer-
roni correction had been performed, the association with 
MI and stroke would be non-significant. Secondly, there 
was no evidence of a dose effect if supplementation was 
assessed in fifths of supplement intake. Thirdly, this was 
not a true time-to-event analysis, with more than one event 
allowed to count in one patient. Fourthly, the safety data 
were recorded in a heterogeneous fashion depending on 
the study and, as has been said previously, were not pri-
mary endpoints of the trials. These caveats are significant 
and numerous enough to call into question the findings of 
the above analysis, and these findings are contradicted by 
re-analyses and further follow-up of the WHI dataset, the 
results of more recent meta-analyses and by large obser-
vational studies.
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Indeed a study by Prentice et al. re-examined the effect of 
calcium and vitamin D supplementation in the WHI clinical 
trial and observational study, with a specific focus on frac-
tures, cardiovascular disease, cancer and all-cause mortality 
[9] and the duration of therapy. They found no associations 
with risks of cardiovascular disease, including MI, coronary 
heart disease, total heart disease or stroke. In support of this 
finding, at 5 years of follow-up, no significant associations 
were observed with any cardiovascular disease outcomes 
(Fig. 1) [10].
Due to the emergence of new data since the meta-analy-
sis by Bolland et al. [6], an updated meta-analysis was per-
formed in 2015 by Lewis et al. [11] particularly examining 
randomised controlled trial data comparing calcium (and 
vitamin D) supplements to non-treatment or placebo controls 
and limiting their analyses to females alone. They included 
18 studies, with a total of 63,563 participants with 3390 
coronary heart disease events and 4157 deaths, and found 
no associations between primary outcomes (coronary heart 
disease and mortality) or secondary outcomes (acute MI, 
angina and chronic coronary heart disease).
Further observational studies have found no increased 
cardiovascular risk with calcium supplementation. A study 
using the UK Biobank (a cohort of 500,000 men and women 
in the UK, aged 40–69 years at baseline) showed incident 
cardiovascular disease in the 10.6% of women and 2.6% of 
men who took calcium supplements [12]. Subsets of patients 
on calcium supplements alone were compared to those on 
calcium and vitamin D, and no effect was observed in the 
incidence of MI, IHD or any cardiovascular outcomes over 
the 5–10 years of follow-up. Within such observational 
studies, there are potential epidemiological issues, includ-
ing confounding by indication, time-varying confounding, 
depletion of susceptible subjects and over-the-counter use of 
calcium and vitamin D, which is common in the UK. One 
explanation for the apparent confusion in this area may be 
in the definition of cardiovascular events. However, even a 
large study including coronary artery computed tomography 
(CT) scans and a mean of 7 years of supplements in ~ 750 
women (aged 50–59 at baseline) demonstrated no associa-
tion [13].
The most recent meta-analysis at the time of writing was 
performed in 2019 by Yang et al. Their meta-analysis of 42 
studies (26 prospective cohort studies and 16 randomised 
controlled trials) of calcium intake, in which cardiovascular 
disease outcomes were recorded, showed that dietary cal-
cium intake of up to 1500 mg/day had no significant effect 
on the risk of cardiovascular disease as a whole or on stroke 
in isolation [14]. However, there was an 8% increased risk 
when MI was examined alone (RR 1.08, 95% CI 1.02–1.15). 
It should be noted that none of the contributing relative risks 
on a study level were significant and the majority of studies 
were observational, representing a lower quality of evidence.
There appears to be no convincing signal for cardiovascu-
lar disease due to calcium [9, 10], even when taken without 
concurrent vitamin D supplementation. Moreover, although 
the theory of increased calcium deposition within blood ves-
sels exists, there are no data available that provide chemi-
cal evidence of this effect [8, 15]. Indeed, calcium intake, 
whether from supplementation or directly from diet, reduces 
blood pressure [16], improves lipid profile [17] and leads to 
transient increases in extracellular and serum calcium and 
thence a short-lived decrease in PTH [18], none of which 
are overtly deleterious to the cardiovascular system. Indeed 
the blood pressure and lipid effects may well be beneficial.
To conclude, calcium supplements and oral calcium 
intake of 1000 mg daily appear to reduce fracture risk, par-
ticularly in institutionalised compared to community-dwell-
ing individuals, but there is no evidence for cardiovascular 
adverse events [9]. There is uncertainty regarding the cardio-
vascular risk of a high daily intake of calcium (in excess of 
1200–1500 mg daily). However, given that higher intakes do 
not have a proven skeletal benefit, excessive calcium intake 
should be avoided in any case.
3  Vitamin D
Cholecalciferol  (D3) (referred to here as vitamin D unless 
otherwise stated) has a plethora of functions, with vitamin D 
receptors found in nearly all the tissues of the human body. 
Fig. 1  Results taken from the Women’s Health Initiative (WHI) trial 
of calcium and vitamin D (CaD) showing the cumulative hazard of 
coronary heart disease (CHD) against time. Intervention (left) and 
post-intervention (right) follow-up are depicted. There was no sig-
nificant difference in the rates of CHD between the CaD and placebo 
arms [10]
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In the cardiovascular system, vitamin D has effects on the 
vascular wall, renin-angiotensin system and cardiac muscle.
In the context of osteoporosis, current guidance recom-
mends vitamin D replacement of 800 international units 
(IU) daily in postmenopausal women at an increased risk 
of fragility fracture, those at an increased risk of vitamin D 
deficiency and those symptomatic of low vitamin D [19].
There are safety issues associated with both an excess 
and a deficiency of vitamin D. Overloading with unusually 
high doses of vitamin D can precipitate hypercalcaemia and 
hypercalciuria. High extracellular calcium concentration in 
the context of primary hyperparathyroidism or vitamin D 
overdose-dependent prolonged hypercalcaemia, vitamin D 
toxicity or any other cause of prolonged hypercalcaemia is 
associated with arrhythmias (including ventricular prema-
ture beats, PR interval prolongation, shortening of the QT 
and broadening of the QRS complex) and calcification (of 
the arterial wall and soft tissues, including the myocardium) 
[20, 21]. There are observational data from Scandinavian 
registries [22], supported by murine studies [23], that sug-
gest a reverse J-shaped association between cardiovascular 
risk and serum 25-hydroxy vitamin D levels, with increased 
cardiovascular risk with lower (12.5 nmol/L) and higher 
(125 nmol/L) extremes.
However, a 3-year randomised controlled trial of high-dose 
vitamin D (up to 10,000 IU per day over 3 years) demonstrated 
no difference in tibial arterial calcification [24]. On the other 
hand, a meta-analysis of observational data has shown that 
if a patient is vitamin D deficient, insufficient or inadequate 
there is an increased risk of cardiovascular adverse events [25]. 
Whether this is a causal association remains in question, as 
the same finding has not been borne out in Mendelian ran-
domisation [25]. A participant-level meta-analysis of vitamin 
D intervention studies for cardio-metabolic outcomes found 
no effect of vitamin D on systolic blood pressure or glycated 
haemoglobin (HbA1c), although there was a reduction in 
low-density lipoprotein cholesterol of − 0.10 mmol/L (95% 
CI − 0.20 to − 0.00), − 0.10 mmol/L (95% CI − 0.18 to − 0.02) 
and − 0.07 mmol/L (95% CI − 0.14 to − 0.00) for subgroups 
with < 75, < 100 and < 125 mmol serum levels of vitamin D, 
respectively [26].
Data from the UK Biobank suggest that there is no asso-
ciation between calcium and vitamin D supplementation and 
incident ischaemic cardiovascular events or death [12].
The Vitamin D and Omega-3 Trial (VITAL) randomised 
over 25,000 individuals (mean age 67 years, 50.6% women) 
who received either 2000 IU per day of vitamin D or placebo 
(and either omega-3 supplementation or placebo). Partici-
pants were followed up for a median of 5.3 years. Investiga-
tors found that there was no association between cardiovas-
cular disease and vitamin D supplementation [27].
However, vitamin D supplementation does not appear to 
prevent cardiovascular disease. The Vitamin D Assessment 
(ViDA) study in New Zealand included about 5000 par-
ticipants (aged 65.9 years, 41.9% women) who were ran-
domised to vitamin  D3, 100,000 IU per month (including 
a 200,000 IU loading dose at baseline) and followed up for 
3.3 years. Vitamin D did not protect against cardiovascular 
disease [28], but vitamin D supplementation improved arte-
rial function in those with vitamin D deficiency.
The most recent meta-analysis investigating the effect 
of vitamin D supplementation on cardiovascular disease 
included 21 randomised controlled trials (including VIDA 
and VITAL), with more than 83,000 individuals, and, once 
again, found that vitamin D supplementation did not confer 
cardiovascular protection [29]. It should be noted that many 
of these individuals were healthy and not osteoporotic.
In conclusion, at the usual dosages of vitamin D (800 IU 
daily) used to prevent vitamin D deficiency in patients with 
osteoporosis [30], there is no evidence for increased cardio-
vascular events. Findings of a protective effect are largely 
from observational datasets, and these have not been borne 
out in randomised controlled trials with cardiovascular dis-
ease as the primary or co-primary outcome or in Mendelian 
randomisation studies. The association between low vitamin 
D and cardiovascular disease may therefore be an epiphe-
nomenon or potentially be due to differences in reference 
ranges [31].
4  Menopausal Hormonal Therapy
Current evidence suggests that MHT is an effective therapy 
for fracture prevention in the early menopause, with reduc-
tions in hip and vertebral fractures [32].
The postmenopausal state is inherently associated with 
a greater risk of cardiovascular disease than the pre-meno-
pausal state. This was observed in women aged 40–50 years 
at the advent of the Framingham cohort with a higher inci-
dence of coronary heart disease and cardiovascular events 
[33–35].
It is important to understand the history and chronology 
of the investigation of cardiovascular disease and MHT, 
which can be divided into four phases.
The first phase (pre-2002) was characterised by the sup-
position that the benefits of MHT outweighed the risks, and 
it was widely used for prevention and treatment of menopau-
sal symptoms. It was therefore one of the most prescribed 
medications at the time, peaking in 2001, with 40% of post-
menopausal women using MHT [36, 37]. Observational 
studies of the time suggested a potential benefit to cardiac 
health (with up to a 50% reduction in coronary heart dis-
ease). However, more recently, these studies have been heav-
ily criticised due to methodological flaws [38].
The second phase was marked in 2002 by the publication 
of data from the WHI. This study included postmenopausal 
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females aged 50–79 who had taken MHT for a mean of 
5.2 years. Those women with an intact uterus (n = 16,608) 
were randomised to placebo or combination MHT (conju-
gated equine estrogens [CEE] and medroxy-progesterone 
acetate [MPA]) due to the risks of endometrial cancer asso-
ciated with unopposed estrogen use. Those in the combi-
nation MHT arm had an increased risk of coronary heart 
disease (HR 1.29, 95% CI 1.02–1.63), stroke (HR 1.41, 95% 
CI 1.07–1.85) and pulmonary embolism (HR 2.13, 95% CI 
1.39–3.25) [39]. Those who had undergone hysterectomy 
(n = 10,739) were randomised to placebo or CEE alone. 
In the CEE-only arm, an increased risk of stroke only was 
observed (HR 1.39, 95% CI 1.10–1.77) [39]. This signal 
of increased cardiovascular and thromboembolic risk with 
combination MHT and increased risk of stroke with both 
combination and CEE-only MHT prompted a statement 
that MHT led to an increased risk of cardiovascular disease 
“irrespective of age, ethnicity or health” and was followed 
by a wave of research into the safety of MHT. The usage of 
MHT was significantly affected, with reduced use of oral 
formulations [40] and an increase in transdermal MHT [41]. 
Nevertheless, it should be acknowledged that the previous 
observational studies were in younger participants, who 
largely had menopausal symptoms, which the majority in 
the WHI study did not, and the age of the WHI participants 
was older than the mean age of menopause in Europe or 
North America, 51 years [37].
It is therefore appropriate that the third phase of MHT 
investigation was marked by analysis of the age-stratified 
data (into age ranges of 50–59, 60–69 and 70–79 years) 
from the WHI study [41], which led to some interesting and 
practice-influencing findings. In the original WHI study, 
16,608 participants received combined MHT. Women in 
their 70s had an increased absolute risk of coronary heart 
disease, venous thromboembolism (VTE) and stroke com-
pared to women in their 50s [42–44]. Women in their 60s 
had an increased risk of VTE and stroke (though not coro-
nary heart disease) compared to women in the youngest age 
group, and the highest cardiovascular event risk was for 
VTE, which increased with increasing age [42]. The results 
for the 50–59 years age group (or for those less than 10 years 
since the menopause) can be seen in Fig. 2, which shows 
an increased risk of VTE and stroke, but apparent benefit 
regarding coronary artery disease and overall mortality.
In the unopposed estrogen group (n = 10,739), younger 
women (aged 50–59 years) were at a low absolute risk of 
all adverse events, although the highest risk was associated 
with VTE, which, similar to the findings of the combined 
MHT group, increased with increasing age [45, 46]. The 
highest absolute risk of a cardiovascular adverse event was 
associated with thrombotic (ischaemic) stroke in the 60–69 
and 70–79 years age groups [46].
When all women taking MHT were analysed together, 
regardless of hormonal constituents of MHT, the absolute 
risk of all cardiovascular adverse events was low in the 
youngest group (50–59 years) (absolute excess risk − 6 per 
10,000 person-years), but higher in the 70–79 years age 
subset (absolute excess risk 17 per 10,000 person-years) 
[47]. The risk of stroke did not vary significantly with age, 
although it was increased in those patients taking hormone 
therapy (HR 1.32, 95% CI 1.12–1.56).
These findings had two main effects. Firstly, it shifted the 
adverse effects of concern away from coronary heart disease 
and towards thromboembolic disease (comprising VTE and 
embolic stroke) [48]. Secondly, it spawned the concept of a 
window of opportunity in which to use MHT, which became 
a theory named the ‘Timing Hypothesis’. This hypothesis 
was also supported by non-human primate randomised con-
trolled trials, which found that estrogen replacement reduced 
atherosclerosis if provided soon after ovariectomy (though 
not if commenced years later) [49].
The development of atherosclerotic plaques is known 
to increase with increasing age, and it may well be that 
the delivery of MHT to those with established atheroscle-
rotic disease, predominantly after the age of 60 years, may 
not have the same protective effects against the develop-
ment of plaques as in younger women under the age of 
60, or within 10 years of the menopause. Indeed, with the 
advance of atherosclerotic plaques, there is a loss of estro-
gen receptor expression (ERα and ERβ) in the vasculature, 
which leads to a loss of estrogen-related vasculoprotection 
and an increase in the pro-inflammatory effects of exoge-
nous estrogens, which could lead to worsening of vasculo-
pathology [49, 50]. There is therefore a possible biochemi-
cal and histopathological mechanism behind the ‘Timing 
Hypothesis’, and it was further investigated through two 
randomised controlled trials: the Kronos Early Estrogen 
Prevention Study (KEEPS) [51] and Early Versus Late 
Intervention Trial With Estradiol (ELITE) [52]. KEEPS 
found a mixed effect on biomarkers of cardiovascular risk, 
but no detectable effect of MHT (oral and transdermal 
estrogens combined with oral progesterone vs placebo) on 
either the advancement or retardation of atherosclerotic 
progression (as measured by carotid artery intima-media 
thickness) in ‘recently menopausal’ women [51]. ELITE 
randomised 643 healthy women to oral 17β-estradiol and 
progesterone vaginal gel or placebo, stratified according 
to time since the menopause. Again, using carotid artery 
intima-media thickness, they found no significant differ-
ence between MHT and placebo in those > 10 years since 
the menopause, but a significantly lower carotid intima-
media thickness (CIMT) change in those on MHT com-
pared to placebo in those < 6 years since the menopause 
[52]. This supports the ‘Timing Hypothesis’ and suggests 
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that a window of opportunity for the use of MHT exists in 
those < 10 years since the menopause.
This is relevant when considering the initial findings of 
the WHI study, in which the participants were typically over 
the age of 60 years [39]. This would place the participants in 
an older age category when, potentially, atherosclerotic dis-
ease is already more advanced and the advantages of MHT, 
in a cardiovascular respect, are lost.
Regarding stroke, the risk of ischaemic stroke with MHT 
may be solely related to oral route of administration, with 
lower oral doses associated with lower risk and transdermal 
administration associated with low risk or no risk at all [53, 
54].
Considering VTE, observational studies and possible 
biological mechanisms suggest a lower risk of VTE with 
low-dose transdermal therapy [55] and some progestogens 
(MPA, norpregnane derivatives and continuous combined 
regimens) may be associated with a greater risk of VTE 
in oral MHT users [53]. The risk of VTE may therefore be 
affected by the estrogenic route of administration, the dosage 
of progestogen and the type of progestogen used [48, 56]. 
Indeed, the effect of progestogens depends on their down-
stream mineralocorticoid and androgenic effects.
The fourth phase is characterised by reflections on the 
story of MHT thus far, which has been aptly expressed in 
the following statement by Manson et al: “The reluctance to 
treat menopausal symptoms has derailed and fragmented the 
clinical care of midlife women, creating a large and unneces-
sary burden of suffering” [57]. This is a sobering thought, 
although when safety concerns exist, it is absolutely right 
that interventions should be withheld whilst further informa-
tion is gathered.
The benefit/risk balance for MHT is most favourable in 
younger, recently postmenopausal women [58, 59] (those 
who are less than 60 years old or within 10 years of the onset 
of the menopause), in the context of menopausal symptoms 
and low baseline risk of breast cancer, cardiovascular and 
cerebrovascular events and venous thromboembolic disease 
[59, 60]. MHT reduces fracture risk in populations unse-
lected for low bone mineral density, but the evidence for 
long-term persisting benefits after cessation of treatment 
is limited [39, 58]. International guidance on MHT varies, 
with a global consensus statement in 2016 recommend-
ing that MHT could be commenced for women aged less 
than 60 years (or within 10 years of the menopause) for 
the reduction of fracture risk, whereas other guidelines have 
suggested that a reduction in fracture should be viewed as an 
additional benefit in the context of treatment of menopausal 
symptoms [59, 61]. Although transdermal preparations are 
associated with a lower risk of VTE, any beneficial effects 
on fracture risk are yet to be proven [59].
In conclusion, while guidelines differ in the approach 
to skeletal health as a primary treatment indication, there 
is a general consensus that MHT has an important role in 
younger, recently postmenopausal women with low base-
line risk of breast cancer, cardiovascular and cerebrovascular 
events and venous thromboembolic disease for the treatment 
of menopausal symptoms, in which context, its positive 
effects on bone health are an additional and welcome benefit.
Fig. 2  The risk–benefit profile 
for estrogenic and combined 
menopausal hormone therapy 
in numbers of women (aged 
50–59 years, or less than 
10 years since the menopause) 
per 1000 per 5 years of use. 
Looking specifically at the 
cardiovascular risks, risks of 
venous thromboembolism and 
stroke are increased through the 
use of both combined and estro-
gen-only formulations, although 
there appears to be a protective 
effect on coronary heart disease 
and overall mortality [48]
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5  Tibolone
Tibolone is a synthetic steroid with estrogenic, progesto-
genic and androgenic properties used primarily for the treat-
ment of postmenopausal osteoporosis and postmenopausal 
symptoms and was the subject of the Long-Term Interven-
tion on Fractures with Tibolone (LIFT) study, a randomised, 
placebo-controlled trial. Over a median 34 months of treat-
ment, compared to placebo, tibolone was associated with a 
reduced risk of vertebral fracture (70 cases vs 126 cases per 
1000 person-years; relative hazard 0.55, 95% CI 0.41–0.74) 
and a reduced risk of nonvertebral fracture (122 cases vs 166 
cases per 1000 person-years; relative hazard 0.74, 95% CI 
0.58–0.93), but an increased risk of stroke (relative hazard 
2.19, 95% CI 1.14–4.23), which led to the discontinuation 
of the study by the safety board [60].
6  Selective Estrogen Receptor Modulators
The major SERM used in the treatment of osteoporosis is 
raloxifene, although bazedoxifene (which may be combined 
with conjugated estrogens) and lasofoxifene (which has a 
limited distribution in parts of Europe) are included in this 
drug class.
SERMs have potential effects on lipid profile [61], inflam-
matory mediators [62], platelet function [63], coagulation 
[61] and glucose metabolism [64], although none of these 
effects are consistently demonstrated in the basic scientific 
literature. Although vasodilatory effects have been observed 
[65], there is no effect on blood pressure in clinical studies 
[66]. Significant associations with cardiovascular disease 
have been observed in trials and, latterly, in meta-analysis.
One such meta-analysis demonstrated a significant 
increase in the risk of venous thromboembolic disease 
(including deep venous thrombosis [DVT] and pulmonary 
emboli [PE]) from the analysis of nine trials (24,523 post-
menopausal women), with an increased odds of any VTE 
(odds ratio [OR] 1.62, 95% CI 1.25–2.09), DVT (OR 1.54, 
95% CI 1.13–2.11) and PE (OR 1.91, 95% CI 1.05–3.47) 
[67] associated with raloxifene usage. Similar associations 
are observed with lasofoxifene (with a dose-related increase 
in cumulative incidence of VTE) [68], and there was a trend 
towards an increased risk of VTE with bazedoxifene (RR 
1.56, 95% CI 0.92–2.64). The increased risk of VTE with 
SERMs is therefore supported by the current literature. 
However, with coronary artery disease, there has been more 
conjecture.
The Multiple Outcomes of Raloxifene Evaluation 
(MORE) study was a randomised, placebo-controlled trial, 
and in a subset of women at high cardiac risk (cardiovascular 
risk score ≥ 4), raloxifene appeared to be protective against 
coronary events over 4 years (RR 0.60, 95% CI 0.38–0.95) 
[69]. However, after 8 years of follow-up, there was no pro-
tective or detrimental effect of raloxifene [70].
In the Raloxifene for the Use of the Heart (RUTH) trial, 
there was no demonstrable cardiac benefit of raloxifene com-
pared to placebo; neither was there a significant difference in 
mortality rates, cardiovascular disease or stroke [71]. How-
ever, those in the raloxifene arm were at an increased risk 
of fatal stroke (HR 1.49, 95% CI 1.00–2.24; absolute risk 
increase 0.7 per 1000 woman-years). A similar trend was 
observed with lasofoxifene (although the HR did not reach 
significance: HR 2.39, 95% CI 0.84–6.78), potentially sup-
porting a class effect [72].
In conclusion, there appears to be a significant increase in 
the risk of VTE with SERMs, and this should guide clinical 
practice. There is no evidence to support the use of ralox-
ifene for cardiac benefit in women at high risk for cardio-
vascular disease, and there may be an increased risk of fatal 
stroke with SERMs, but not overall strokes, cardiovascular 
disease or mortality rate.
7  Bisphosphonates
When examining the cardiovascular safety of the bisphos-
phonates, the key issues are the possible association with 
atrial fibrillation and the potential atherosclerotic protection 
afforded by this group of anti-osteoporosis interventions.
The cardioprotective effects of bisphosphonates are 
debated [73, 74]. Animal studies in pigeons fed an ath-
erogenic diet demonstrated a reduction in atherosclerotic 
plaque size and percentage with a non-nitrogen bispho-
sphonate, etidronate [75]. A study in monkeys has also 
demonstrated reduction in diet-induced atherosclerosis 
following treatment with anti-calcifying agents, includ-
ing bisphosphonates, independent of changes in circulating 
lipid profiles [76].
Other mechanisms for the potential cardiovascular benefit 
of bisphosphonates include improvement of arterial elas-
ticity, decrease in systemic vascular resistance and carotid 
artery intima-media thickness [77], inhibition of the meva-
lonate pathway (preventing ischaemia-induced myocardial 
remodelling and cardiac function) [78], inhibition of intra-
vascular calcification [79] and a decrease in circulating γδ 
T cells, which are known to stimulate atherosclerotic pro-
gression [80].
These findings from animal studies are interesting, but 
it must be noted that they could be potentially due to dose 
effects, as higher doses were used in animal models than are 
utilised in clinical trials and practice. Indeed, the evidence 
discussed below pertains to the doses used in the context of 
osteoporosis, which are lower than those employed within 
the context of oncology.
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The present analysis concerns doses used in the treat-
ment of osteoporosis. Regarding the mortality and morbidity 
data from the early phase 3 controlled trials for risedronate, 
there is a discernible trend towards reduced cardiovascular 
mortality, though not on overall mortality, in those treated 
with risedronate compared to placebo [81]. However, a 
closer examination reveals a more mixed picture. The rates 
of cardiovascular adverse events (rather than mortality), 
coronary artery disease and stroke were numerically very 
similar for placebo, 2.5 mg risedronate and 5 mg risedronate, 
with no significant difference seen. When focussing on any 
cardiovascular mortality, the protective effect of risedronate 
was only observed in the 2.5-mg group (RR 0.69, 95% CI 
0.49–0.99) and not in those taking 5 mg (RR 0.84, 95% CI 
0.60–1.17). A similar picture was seen with stroke mortality 
for the 2.5-mg (RR 0.36, 95% CI 0.17–0.78) and 5-mg (RR 
0.64, 95% CI 0.34–1.20) groups. There was no protective 
effect observed for mortality from coronary artery disease, 
which, given the proposed biological mechanisms for bis-
phosphonate cardiovascular protection, would be suspected 
to be the most amenable pathology to treatment.
Zoledronic acid was the subject of the Health Outcomes 
and Reduced Incidence with Zoledronic Acid Once Yearly 
(HORIZON) trial [82], which found similar rates of cardio-
vascular events and stroke, although there was a reduction 
of 28% in all-cause mortality in the zoledronic acid group 
(9.8% mortality vs 13.3% mortality, p = 0.01) [83]. In the 
Fracture Prevention with Zoledronate in Older Women with 
Osteopenia trial [84] (in osteopenic rather than osteoporotic 
older women with an 18-month interval in zoledronic acid 
administration), the HR for MI in the zoledronic acid group 
was 0.60 (95% CI 0.36–1.00) and the rate ratio was 0.58 
(95% CI 0.35–0.94). For a pre-specified composite cardio-
vascular endpoint (sudden death, MI, coronary artery revas-
cularisation or stroke), the HR was 0.76 (95% CI 0.53–1.08) 
and the rate ratio was 0.72 (95% CI 0.53–0.98) [85].
The absence of a true cardiovascular benefit of bisphos-
phonate therapy is supported by findings from an analysis 
of two large (> 47,000 participants), long-term, prospective 
databases in the USA, which demonstrated no statistical dif-
ference in the long-term rates of MI or death [86]. Interest-
ingly, in this study, the patients who underwent coronary 
angiography were investigated as a high-risk subgroup and, 
again, no benefit of bisphosphonate therapy was observed 
[86].
The possible cardioprotective effects of bisphosphonates 
remain under scrutiny, and there is certainly not sufficiently 
robust, cohesive data to support a recommendation for this 
class of medications to be used to treat cardiovascular dis-
ease, or even to recommend using them to treat osteoporosis 
in those at high risk of MI or stroke. A recent meta-analysis 
reported that mortality was not altered by bisphosphonate 
treatment [87].
The connection between bisphosphonates and arrhythmia 
has an equally mixed picture. Early analysis of the safety 
data from the HORIZON trial demonstrated a significantly 
higher incidence of arrhythmia in the zoledronate arm (6.9% 
vs 5.3% in the placebo arm, p = 0.003) and that within this 
group ‘serious atrial fibrillation’ (atrial fibrillation that 
resulted in a serious adverse event) was significantly more 
common (1.3% vs 0.5% in the placebo arm, p < 0.001) [82]. 
A similar trend had been previously observed in the Frac-
ture Intervention Trial (of alendronate) [88], but although 
the cumulative incidence of serious atrial fibrillation had 
numerically increased with alendronate, the rise had not 
been statistically significant.
Further studies sought to investigate this association, 
with conflicting findings. A case–controlled study from a 
healthcare database in the USA found that a greater num-
ber of atrial fibrillation case patients than controls had ever 
used alendronate (6.5% vs 4.1%, p = 0.03) and that when 
comparing ever-users (of bisphosphonates) to never-users, 
the ever-users had a higher risk of incident atrial fibrillation 
(OR 1.86, 95% CI 1.09–3.15) [89]. However, a European 
population-based, case–control study (comparing ~ 13,500 
patients with atrial fibrillation or flutter to ~ 68,000 controls) 
found no evidence of increased risk of arrhythmia with bis-
phosphonates [90]. This finding was supported by another 
European case–control, register-based cohort study, which 
found that the highest risk of atrial fibrillation was in the 
subgroup of patients who only received the bisphosphonates 
once and the longer the patient was adherent to bisphospho-
nates, the lower the risk of atrial fibrillation [91].
An interesting hypothesis from the latter study was that 
fracture patients were inherently more likely to experience 
atrial fibrillation (compared to non-fracture controls) and 
more likely to receive bisphosphonates, thus confounding 
the association [91]. This theory was supported in the afore-
mentioned study of two large prospective databases, which 
found that patients on bisphosphonates were inherently older 
with a greater cardiovascular disease burden, thus increasing 
their risk of atrial fibrillation.
Considering that the majority of the signal is for an 
increased risk of atrial fibrillation with bisphosphonate 
therapy came from the HORIZON trial and zoledronic acid, 
it should be acknowledged that in the Recurrent HORIZON 
trial (consisting of a more elderly, infirm, post-hip frac-
ture population), there was no significant increase in seri-
ous atrial fibrillation [83]. Neither was atrial fibrillation 
increased in those on zoledronate in the PREVENTION 
study (a 6-year randomised, placebo-controlled trial of 2000 
women) [84].
Therefore, in conclusion, there is no substantial signal for 
the development of atrial fibrillation with bisphosphonates 
at present, though further studies examining and powered to 
answer this exact question are warranted.
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8  Denosumab
Denosumab (60 mg, every 6 months) is a fully human mono-
clonal antibody and inhibitor of receptor activator of nuclear 
factor-κB (RANK) ligand, which prevents the maturation 
and activity of osteoclasts and therefore acts to reduce bone 
resorption. There is a potential, though tenuous, link with 
cardiovascular health via RANK-ligand, RANK and oste-
oprotegerin (OPG). OPG is found in calcifications in the 
aorta and renal arteries, and transgenic overexpression of 
OPG leads to inhibition of these calcified vascular lesions. 
Indeed, when an atherogenic mouse model was treated with 
OPG, there was a significant reduction in calcified lesions. 
RANK-ligand itself is known to induce calcification of vas-
cular smooth muscle, and the development of vascular cal-
cifications depends on RANK-ligand–mediated expression 
of bone morphogenetic protein-2 (BMP-2) and matrix Gla 
protein. Thus OPG could potentially inhibit the formation of 
vascular calcifications by blocking RANK-ligand and there 
is thus a plausible biological mechanism for some prevention 
of cardiovascular pathology when treated with denosumab. 
This is, however, not borne out by the evidence from ran-
domised controlled trials.
The Fracture Reduction Evaluation of Denosumab in 
Osteoporosis Every 6 Months (FREEDOM) study was a 
phase 3, multicentre, double-blind, placebo-controlled trial 
of denosumab over 3 years [92]. It included a total of 7868 
women (with 31.7% of these ≥ 75 years), and throughout this 
initial trial period, there was no significant difference in car-
diovascular events, stroke, coronary heart disease, peripheral 
vascular disease or atrial fibrillation [92]. Despite the fact 
that FREEDOM was not powered to investigate mortality, 
there was a non-significant trend towards reduced mortality 
in the denosumab group (1.8% participants in denosumab 
group vs 2.3% participants in the control group, p = 0.08) 
[92].
In 2014, there was a further analysis of a subset of 2363 
women (1142 placebo, 1221 denosumab) from the FREE-
DOM trial who were at high risk of cardiovascular disease 
(as defined by the RUTH criteria) [93]. In this study, aortic 
calcification and progression was assessed using a semi-
quantitative method from lateral spine radiographs. There 
was no significant difference in aortic calcification progres-
sion over the 3 years of the trial between the placebo (22%) 
and denosumab (22%) groups and no difference in cardio-
vascular risk across the two groups (in the high cardiovas-
cular risk population) [93].
In conclusion, although a plausible biological connec-
tion exists between denosumab and cardiovascular disease, 
there is no evidence from human trials to support a positive 
or negative effect on cardiovascular risk, at least at the dose 
used in osteoporosis therapy.
9  Parathyroid Hormone Analogues
It has long been known, initially from animal studies, that 
PTH has chronotropic effects via receptors in cardiac myo-
cytes and transient dilatory effects on the peripheral vascu-
lature, leading to an increase in heart rate and reduction in 
blood pressure, respectively [94]. These effects may have 
manifested as adverse events in the trials for the two PTH 
analogues that are currently used in osteoporosis clinical 
practice: teriparatide and abaloparatide.
The Summary of Product Characteristics for teriparatide 
lists nausea, headache and dizziness as potential adverse 
effects, which could potentially be related to the cardio-
vascular mechanisms described above from animal studies. 
Indeed in the VERtebral Fracture Treatment Comparisons 
in Osteoporotic Women (VERO) trial comparing teripara-
tide to risedronate, there was a significantly higher inci-
dence of dizziness (teriparatide 30 [4.4%], risedronate 12 
[1.8%], p = 0.007) in those taking teriparatide, but there was 
no excess incidence of cardiovascular adverse events [95]. 
Even in post-marketing surveillance, there was no percepti-
ble signal of increased risk of cardiovascular adverse events, 
as demonstrated by a Japanese, prospective, observational 
study [96].
A similar story was observed in the Abaloparatide Com-
parator Trial in Vertebral Endpoints (ACTIVE) [97], which 
included teriparatide and placebo arms. In the abaloparatide 
arm, discontinuation of the study drug was most commonly 
due to nausea (1.6%), dizziness (1.2%), headache (1.0%) and 
palpitations (0.9%). Dizziness had a higher incidence in the 
abaloparatide group (10.0%) than in the teriparatide group 
(7.3%) or placebo group (6.1%). However, ‘dizziness’ is a 
symptom with both potential cardiovascular and neurologi-
cal aetiology, and it is therefore interesting that the more car-
diovascular endpoint of orthostatic hypotension was defined 
as an adverse event of special interest and was very similar 
across all three arms (17.1% in the teriparatide arm, 16.4% 
in the placebo arm and 15.5% in the teriparatide arm) sug-
gesting a lack of association. Palpitations were most com-
mon with abaloparatide (5.1%), with a lower incidence with 
teriparatide (1.6%), and placebo being the lowest (0.4%). 
There was no excess risk of MI, falls or syncope.
In conclusion, animal models have demonstrated poten-
tial effects of PTH on the cardiovascular system [94], and 
these may lead to increased rates of dizziness [95] with PTH 
analogues. However, whether this increased risk is mani-
fested via the cardiovascular system is not clear, and there 
is certainly no current evidence to suggest an increased risk 
of atherosclerotic or thromboembolic cardiac disease with 
this group of interventions.
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10  Romosozumab
Romosozumab is a humanised monoclonal antibody, 
approved by the Food and Drug Administration (FDA) [98] 
and European Medicines Agency (EMA) [99], which inhib-
its sclerostin. Sclerostin is an effective antagonist of Wnt 
signalling, and thus romosozumab acts as an anabolic agent 
for bone formation and as an inhibitor of bone resorption. 
Controversy exists regarding the cardiovascular safety of 
this drug from the point of biological plausibility, the out-
comes of randomised controlled trials [100–102] and the 
output of meta-analyses [103]. Current guidance (in some 
regions) advocates against use in those with a history of MI 
and ischaemic stroke and recommends a judicious approach 
in those with a high baseline risk of cardiovascular disease 
[99, 104].
The arguments for the biological plausibility of adverse 
cardiovascular effects of romosozumab centre on a potential 
role in arterial calcification. Sclerostin is the product of the 
SOST gene and is primarily secreted by osteocytes. It plays 
an important role in bone turnover by upregulating bone 
formation and downregulating bone resorption [101, 105]. 
Beyond the skeleton, increased sclerostin expression has 
been observed in smooth muscle tissue in areas of vascular 
calcification [106]. At these sites, sclerostin may act to limit 
the formation of calcified plaques [107] and confer a degree 
of cardiovascular benefit.
In a murine model of increased cardiovascular risk, apoli-
poprotein E (apoE)-null mice (prone to aortic aneurysm and 
atherosclerosis) were provided with an infusion of angio-
tensin II [108]. They were then subjected to sclerostin from 
either transgenic overexpression or exogenous recombinant 
murine sclerostin. Increased sclerostin, from either source, 
was found to be protective against aortic aneurysm forma-
tion and atherosclerosis. This was further supported by data 
from experiments in which a murine model of glucocorti-
coid-induced osteopenia was crossed with a Sost-deficient 
(and therefore sclerostin-deficient) mouse [109], with result-
ant sudden death in ~ 10% of mice. On post-mortem, histo-
pathological evidence of peracute haemopericardium and 
cardiac tamponade was observed. These murine data support 
the theory of a cardiovascular protective effect of sclerostin.
This has resulted in the hypothesis that romosozumab-
induced sclerostin inhibition could modulate Wnt-β-catenin 
signalling [110] via a compensatory increase in expression 
of Dickkopf Wnt signalling pathway inhibitor 1 (DKK1) 
[111] to result in vascular calcification and destabilisation 
of atherosclerotic plaques [112].
However, this effect of romosozumab has not been clearly 
demonstrated in animal models. Indeed, the administration 
of romosozumab did not significantly alter DKK1 levels in 
a rat model of progressive renal osteodystrophy [113] or 
ovariectomised cynomolgus monkeys in response to romo-
sozumab [114].
In human conditions associated with reduced activity of 
sclerostin, neither van Buchem’s disease nor sclerosteosis 
demonstrate cardiovascular disease manifestations [115, 
116], although it should be noted that a substantial propor-
tion of homozygous individuals die in early adulthood (mean 
age of death 33 years) due to complications of increased 
intracranial pressure [117], and the effect of sclerostin inhi-
bition in an older age-group may be different.
As described above, although there are potential hypoth-
eses, there is not a robust demonstration of a biological basis 
for cardiovascular disease related to romosozumab.
The FRActure study in postmenopausal woMEn with 
osteoporosis (FRAME) was a randomised controlled trial 
comparing romosozumab to placebo, before transitioning 
onto denosumab [100, 101]. In this trial, there were no 
observed associations between romosozumab and cardio-
vascular adverse events, including major adverse cardiac 
events (MACE) (a composite of non-fatal MI, non-fatal 
stroke and cardiovascular death), with an HR of 1.1 (95% CI 
0.7–1.7). In the FRAME extension study, the percentage of 
positively adjudicated adverse cardiac events did not differ 
significantly, with 3.6% for romosozumab and 3.5% for pla-
cebo [118]. However, it should be noted that the participant 
population included women with a broad range of osteopo-
rosis severity, rather than being focused only on those with 
severe disease.
The Active-Controlled Fracture Study in Postmenopau-
sal Women with Osteoporosis at High Risk (ARCH) [102] 
compared romosozumab to alendronate, before transitioning 
onto long-term alendronate therapy. Unlike FRAME, ARCH 
did focus on individuals with severe osteoporosis, and there-
fore the participant group was older and had a higher base-
line prevalence of cardiovascular disease and risk.
Although ARCH was designed and powered to assess effi-
cacy in the treatment of osteoporosis, the primary cardiac 
safety endpoint was serious cardiovascular adverse events 
(composed of MACE outcomes [non-fatal MI, non-fatal 
stroke and cardiovascular death] plus heart failure and non-
coronary heart disease), and this did not differ significantly 
between treatment groups (2.5% romosozumab and 1.9% 
alendronate; HR 1.32, 95% CI 0.87–2.01, p = 0.2) [102]. 
In post hoc analyses of MACE, the incidence was 2.0% in 
the romosozumab group and 1.1% in the alendronate group, 
indicating a significant preponderance for cardiovascular 
disease with romosozumab (HR 1.7, 95% CI 1.1–2.6) [99].
Examining the constituent parts of MACE separately, an 
increased risk of cardiovascular ischaemia was observed in 
the romosozumab group (n = 2040) compared to the alen-
dronate group (n = 2014) (OR 2.65, 95% CI 1.03–6.77) 
[102]. However, there was no increased risk of cerebrovas-
cular disease (OR 2.27, 95% CI 0.93–5.22) or cardiovascular 
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mortality (OR 1.42, 95% CI 0.68–2.97) when analysed in 
isolation, rather than being included with cardiovascular 
ischaemia in the MACE composite endpoint [102]. It is 
important to note that, in ARCH, any undisclosed cause of 
death was recorded as a cardiovascular death, which may 
have led to overestimation [99]. Interestingly, the incidence 
of heart failure, non-coronary revascularisation and periph-
eral vascular ischaemic events not requiring revascularisa-
tion was lower in the romosozumab arm [102].
A numerical preponderance towards cardiac adverse 
events was observed (as a non-primary outcome) in pla-
ceBo-contRolled study evaluatIng the efficacy anD safety of 
romosozumab in treatinG mEn with osteoporosis (BRIDGE) 
(which examined the bone health of 170 males) [119]. Only 
ten participants experienced positively adjudicated serious 
cardiovascular adverse events, 4.9% with romosozumab and 
2.5% in the placebo group.
Therefore, the bulk of evidence against the cardiac safety 
of romosozumab comes from the ARCH trial [102]. This 
has been the subject of commentaries defining the possible 
explanations for the increased risk of MACE with romo-
sozumab shown in this study as being due to increased car-
diac risk of romosozumab, or the decreased cardiac risk with 
alendronate or the result of a chance finding [120].
Previously in this paper, we examined the potential car-
diovascular protective effect of bisphosphonates and con-
cluded that there was no robust evidence to support this sup-
position (particularly over the short, 12-month study period 
of ARCH). Indeed, there is evidence against either drug 
effect, as once participants were switched to alendronate, 
there was no change in cardiovascular disease risk [99]. 
Additionally, there was no apparent inflection of the slope 
of the cumulative incidence plot of time to first occurrence 
of MACE as participants switched from romosozumab to 
alendronate [99], suggesting that there was either no change 
in the risk of MACE or that the risk of MACE accrued by 
romosozumab was constant after the 12 months of treatment.
The ARCH population had significantly greater car-
diovascular risk factors and a greater history of previous 
cardiovascular events than the FRAME population, which 
may have implications for the safety of the drug in an older 
population. In addition, when all the data were considered 
together, there were more deaths in patients aged over 
75 years given the medicine [121]. However, subgroup 
analyses from ARCH demonstrated no difference in the 
cardiovascular risk between high- and low-risk subgroups 
(including those aged < 75 or ≥ 75, ever or never smokers 
and use of cardiovascular disease medications at baseline) 
[99].
When all these results were meta-analysed for the asso-
ciation between romosozumab and cardiovascular disease, 
the associations were non-significant for MACE (1.39, 95% 
CI 0.97–2.00) and serious adverse cardiovascular events 
(1.14, 95% CI 0.85–1.53). In support, a recent meta-analysis 
of six trials found a 39% increased risk of 4-point MACE 
(including death, MI, stroke and cardiac failure) with romo-
sozumab, which was statistically significant [103]. When 
examining the cardiovascular adverse event profile of each 
arm in these trials, it is important to remember that the pri-
mary outcomes were efficacy rather than safety related. It is 
also important to note that the results of this meta-analysis 
are driven by the results of ARCH and that the marked dif-
ferences in study populations and design make meta-analysis 
an ineffective approach for ARCH and FRAME [99].
The delay in the decision regarding the benefit–risk bal-
ance of romosozumab when considering cardiovascular 
safety is understandable. The studies undertaken in patients 
with a relatively mild deficit in bone mineral density (the 
best example of which is FRAME) suggest no increase in 
the risk of a major cardiovascular events, but appear to have 
equivocal benefits on non-spine fractures [100, 101]. How-
ever, those studies focussing on older, frail patients with 
more severe osteoporosis and previous fracture demon-
strate marked effectiveness against recurrent fracture but an 
increased risk of MACE and cardiovascular ischaemia with 
romosozumab [102].
Debate may continue as to the extent to which the imbal-
ance in cardiovascular events and mortality represents a 
protective effect of bisphosphonates on IHD compared to 
an adverse increase in risk attributable to romosozumab or 
whether it is a simply a chance effect [120].
For this reason, the EMA have reasonably concluded that 
romosozumab can be used for postmenopausal women with 
severe osteoporosis who are at a high risk of fracture, but 
not in those with a history of MI or stroke [121]. In those 
individuals with a high baseline cardiovascular risk, a robust 
risk–benefit assessment should be performed [99]. We now 
have to wait for data from pharmacovigilance studies that 
have been instigated worldwide to assess this benefit–risk 
balance in larger populations when drug use can be evalu-
ated on a more routine clinical basis.
11  Conclusions
In conclusion, despite past studies demonstrating an asso-
ciation with coronary heart disease, there are no consistent 
data to suggest an association between calcium and coro-
nary artery disease, and vitamin D supplementation does not 
appear to be associated with increased cardiac risk. There is 
a window of opportunity until 10 years after the menopause 
in which to use MHT without apparent detriment regard-
ing cardiovascular disease. SERMs are associated with a 
significantly increased risk of VTE and may be associated 
with fatal stroke. Bisphosphonates cannot be recommended 
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for cardiac benefit, and associations with atrial fibrillation 
are inconsistent. There is no evidence of adverse cardiac 
effects with denosumab or PTH analogues. The signal on 
cardiovascular disease adverse events with romosozumab 
needs post-marketing surveillance, which will be crucial in 
confirming cardiovascular safety.
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